COVID-19 Serology and Immunosenescence

Not Applicable

Active, not recruiting

• Conditions: Immunosenescence; Covid19; Geriatric Medicine; Seroconversion
• Interventions: Biological: blood sample

• Registration Number: NCT04563650
• Lead Sponsor: Centre Hospitalier Universitaire, Amiens

Brief Summary

This study aims to determine how long COVID-19 neutralizing antibodies can be detected in an elderly institutionalized population presenting fragility factors.

This study also aims to stratify seroconversion by immunological profiles of the elderly patients residing in the EHPAD. This stratification requires the measurement of immunological marker levels already described in immunosenescence and also involved in the development of certain chronic infectious diseases more common in the elderly population. This analysis will enable the investigators to describe an immunological, clinical and biological profile representing a patient who has developed an immunity against COVID 19. It will also help the investigators to understand the different mechanisms leading to a reduced immune response after a potential administration of a vaccine. Finally, it will help describe the immune profiles of elderly residents who presented with non-severe forms of COVID-19.

Detailed Description

Not available

Study Timeline

• Study Start: 2020-09-18
• Study First Submitted: 2020-09-18
• Study First Submitted QC: 2020-09-23
• Study First Posted: 2020-09-24
• Primary Completion: 2021-05-01
• Status Verified: 2024-04
• Last Update Submitted: 2024-04-09
• Last Update Posted: 2024-04-10
• Study Completion: 2024-11

Recruitment & Eligibility

• Status: ACTIVE_NOT_RECRUITING
• Sex: All
• Target Recruitment: 98

Inclusion Criteria

• Residents of the EHPAD/USLD St Victor of the Amiens CHU who took part in the screening campaign (RT-PCR and serology) organized by the Amiens CHU
• residents who signed a consent form to participate in the study

Exclusion Criteria

• The patient or his legal representative refused to participate in the study
• Heavily sedated patients

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
COVID-19 positive resident	blood sample	-
COVID-19 negative resident	blood sample	-

Primary Outcome Measures

Name	Time	Method
titers of COVID-19 neutralising antibodies	at 9 months

Trial Locations

Locations (1)

CHU Amiens; 🇫🇷 Amiens, France